Skip to content

Author

M. Schuler

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based chemotherapy in the randomized phase 3 DeLLphi-304 study

Background In the DeLLphi-304 trial, at a median follow-up of <12 months, tarlatamab significantly improved overall survival (OS), progression-free survival (PFS), and patient-reported outcomes (PROs), and demonstrated a favorable safety profile versus chemotherapy. We report efficacy and safety outcomes after extended...

C. Rudin, M.-J. Ahn, M. Schuler et al. · 0 citations
Open access Sep 2026

Real-world survival benefit of adding durvalumab to chemotherapy in cholangiocarcinoma: a retrospective cohort analysis from a German Comprehensive Cancer Centre

Background Advanced biliary tract cancers (BTCs) carry a poor prognosis. Gemcitabine/platinum chemotherapy was the first-line standard until TOPAZ-1 and KEYNOTE-966 established immune checkpoint inhibitor-based combinations as a new standard. Real-world data with a chemotherapy-only comparator remain limited. Patients...

S. Elbasan, S. Kasper, I. Mavroeidi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.